Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2024 Dec 16;18(12):e0012325. doi: 10.1371/journal.pntd.0012325

Factors associated with Onchocerca volvulus transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic: A Cross Sectional Study

Sylvain Honoré Woromogo 1,2,*,#, Stéphanie Inesse Garoua-Adjou 1,#, Ange Donatien Ngouyombo 1,#, Rodrigue Herman Doyama-Woza 2,#, Henri Saint Calvaire Diemer 2,#, Jean de Dieu Longo 2,#
Editor: Richard Reithinger3
PMCID: PMC11684659  PMID: 39680607

Abstract

The Central African Republic has endemic onchocerciasis in 20 health districts in savannah and forest areas. The country organised a mass distribution campaign of invermectin in 2023 through the National Onchocerciasis Control Programme. The objectives of this study were to identify factors of persistent Onchocerca volvulus transmission. A cross-sectional study was carried out in Bossangoa (savannah area) and Kémo (forest area) health districts. Using kelsey’formula 1600 respondents were recruited. Dependent variable is onchocerciasis status. Bivariate analysis was carried out to determine the differential risks for onchocerciasis infection, each variable being taken separately. The strength of statistical associations was measured by prevalence rates (PR) from log-binomial regression model and their 95% confidence intervals. Onchocerciasis prevalence is 26.45% in Bossangoa (95% CI = 23.76–29.14), and 14.79% (84/568) in Kémo (95% CI = 23.53–29.37). In both savannah and forest areas, the common factors incriminated in the transmission of onchocerciasis after several years of community distribution of ivermectin were: young age (PR = 2.44 (1.97–3.03), p < 0.001; 3.63 (2.32–5.70), p < 0.001 respectively), not taking ivermectin (PR = 2.31 (1.86–2.87), p < 0.001; 6.84 (4.42–10.57), p < 0.001 respectively), male sex (PR = 2.54 (2.04–3.16), p <0.001; 1.79 (1.19–2.69), p = 0.002 respectively), living near rivers and in rural areas. Despite efforts, the prevalence of onchocerciasis remained high in the 2 districts. The main factors incriminated in the persistence of transmission were failure to take ivermectin, male sex and young age. The National Onchocerciasis Control Programme needs to review its planning of activities, ensuring that the population is constantly made aware before drugs are distributed, and increasing the number of days of community-based distribution in order to improve therapeutic coverage.

Author summary

Onchocerciasis is a disease called River Blindness and transmitted by the bites of infected blackflies that reproduction is in high-flow streams. This disease affects the skin (itching and nodules) and eyes (redness and even blindness). An effective treatment is ivermectin. Human activities near rivers contribute to the disease. Also, good coverage of ivermectin intake by the population considerably reduces the number of people affected. The question we asked ourselves was: why, after more than 20 years of community-based distribution of ivermectin in the Central African Republic, is onchocerciasis still being transmitted? The study showed that in both the savannah and the forest, men are particularly at risk, not only because of their activities near rivers, but also because they do not protect their bodies as women do. We found a higher number of people affected in rural areas than in urban areas. In the community that adheres to ivermectin use, the number of people affected decreases. We recommended that the national onchocerciasis control programme take into account the habits of the population in order to plan and monitor their control activities (for example: increase the number of days ivermectin is distributed, and the number of days community awareness is raised).

Introduction

Onchocerciasis or river blindness is a parasitic disease caused by the threadworm Onchocerca volvulus [1]. This worm is transmitted to humans by the bites of infected Simuli (or black flies) who reproduce in high-flow streams (rivers). The adult worm produces embryonic larvae (microfilariae) in the human body, which migrate into the skin, eyes and other organs. When a female black fly bites an infected person to feed on their blood, it also absorbs microfilariae and are then transmitted to other humans who are bitten [2].

Onchocerciasis leads to eye and skin complications [3]. Onchocerciasis is observed in three WHO regions: the African Region, the American Region and the Eastern Mediterranean Region. In Africa, onchocerciasis affects twenty-seven countries, and more than 99% of infected people live in sub-Saharan Africa [4]. According to the global burden of disease study estimate, there were 20.9 million O. volvulus infections worldwide in 2017; 14.6 million of the infected people had skin disease and 1.15 million had vision loss [5,6]. From a socio-economic point of view, although the impact of the infestation on longevity is controversial, a study carried out in the West African savannah showed a 13-year reduction in the life expectancy of blind people compared with non-blind people [2]. Some of the consequences of this disease on the lives of people in endemic areas remain a cause for concern [3,4,710].

Treatment of individuals with ivermectin for 10 to 15 years through Mass Drug Administration (MDA) programs annually or biannually was suggested by the African Program for Onchocerciasis Control (APOC) as a means for disease elimination because the ivermectin kills the microfilaria but only partly paralyzes the adult worm, and must be taken for the reproductive lifespan of the worm to counteract transmission. APOC ended in 1995, and individual countries were responsible for ensuring disease elimination [11,12]. In the African region, treatment increased from 119 million in 2015 to 132 million in 2016, and therapeutic coverage rose from 64% to 67% [4].

In the Central African Republic (CAR) onchocerciasis is endemic in 20 health districts in savannah and forest areas. Supported by several partners, the country has organised a mass distribution campaign of ivermectin in 2023 through the National Onchocerciasis Control Programme (PNLOC). One year after this campaign, we wanted to measure the prevalence of the disease in 2 health districts, one in the savannah zone and the other in the forest zone, and to identify the factors that transmit the disease, with the aim of helping to reduce morbidity due to this Neglected Tropical Disease (NTD).

Methods

Ethics statement

The study protocol was validated by the Ethics Committee of the Faculty of Health Sciences of the University of Bangui (« CSCVPER ») (agreement 0019 -UB/-FACSS/CSCVPER). Each participant read and understood the information note for the study. Signed informed consent was obtained from each respondent. Formal written consent was obtained from the parents/guardian for children under the age of 18. Finally, all respondents received a commitment that their data would be anonymised.

Study setting

The study was conducted in two endemic health districts in the CAR: Bossangoa in the savannah zone and Kémo in the forest zone. These two health districts are bordered by rivers with confluences, with a total population of 175,679 and 193,044 respectively and people rear pigs. The main activities in common in these two areas are trade, agriculture, breeding, hunting and other informal activities. We chose these two districts because a mass ivermectin distribution campaign was organised in 2023, with therapeutic coverage of 45% and 81% respectively in Bossangoa and Kémo. Furthermore, members of the management team in these two health districts received training in the diagnosis of Neglected Tropical Diseases in the same year, with the support of partners (WHO, CBM and MDP).

Study design and participants

We conducted a cross-sectional analytical study from 4 January to 30 March 2024. Participants were residents of Bossangoa and Kémo health districts. Anyone over 5 years of age who had been resident in the locality for at least one year and who agreed to take part in the study was included. Participants under 5 years of age, those who had been resident for less than a year and those who refused to take part in the study were excluded. Anyone over 5 years of age who had been resident in the locality for at least one year and who agreed to take part in the study was included. Participants under 5 years of age, those who had been resident for less than a year and those who refused to take part in the study were excluded. For participants under the age of 15, verbal parental consent was required.

Sampling

The sample size for this study was determined using Kelsey’s formula in STAC Calc from EPiInfo for an observational study, for a power of 80%, a ratio of unexposed to exposed of 2 and a 95% confidence interval [13]. Considering a non-response rate of 10%, the final sample size is 1600 participants.

We used a cluster survey to obtain respondents. The clusters were formed from a list of all the villages and neighbourhoods in each health district. This gave us 30 clusters per health district. For each cluster selected, all eligible participants were included in the study. In order to get as many respondents as possible in a cluster or village, awareness-raising sessions were held with village chiefs a week before the survey date. On the survey day, the team explained the purpose of the study to each participant in an information note and obtained informed consent, which was read and signed before the questionnaire was administered, followed by a clinical examination and skin samples.

Variables

The dependent variable was the presence or absence of onchocerciasis. We collected as independent variables i) sociodemographic data (age, sex, occupation, activities, residence, duration of residence of respondents, ii) clinical and medical data (skin and eye disease such as skin desquamation, leopard skin, loss of elasticity, nodules, keratitis, visual impairment and permanent blindness), epileptic seizures, duration of signs, ivermectin intake).

Data collection and tools

A structured questionnaire, pre-tested in another health district and validated, was used to collect data. It was administered in French and Sango (CAR’s other national language) by members of the district team, 6th year medical students and 3rd year nursing students. Members of the health district team who had been trained in onchocerciasis diagnosis briefed the other investigators.

Prevalence of onchocerciasis was determined by individual and community diagnosis. For individual diagnosis, a skin sample (bloodless skin biopsy) was taken and examined for microfilariae, and experienced investigators have used a slit lamp to look for microfilariae in the eye. Dermal microfilariae were detected by examination of the bloodless skin biopsy using Holth 2.3 mm snip forceps. Two samples were collected from the iliac crests, one on the right, the other on the left, and then placed in the wells of a microtiter plate after adding a drop of distilled water. Then the plates covered with parafilm paper. The samples were read within 24 hours of incubation.

Community diagnosis is epidemiological: symptoms of the disease in skin and eyes. For the questions analyzing skin changes, any positive reports from the respondents were checked clinically and confirmed by the interviewer. For epilepsy and seizures, the interviewer made sure the definition of the condition was clear to the respondent, describing the disease in simple words and with example. Symptoms and signs were assessed by 6th year medical students and members of district health management teams trained in the management of onchocerciasis in 2023. Diagnosed respondents are treated.

Data analysis

Anonymised data were entered into an Excel file and analysed using EpiInfo software version 3.5.1. Independent and dependent variables were summarized using descriptive statistics, which were reported as frequencies and proportions for qualitative variables and mean with standard deviation for quantitative variables. The chi-square test was used to compare categorical variables with a significance level of p <0.05.

Results were presented according to onchocerciasis infection status. Thereafter, bivariate analysis was carried out to determine the differential risks for onchocerciasis infection, each variable being taken separately. The strength of statistical associations was measured by prevalence rates (PR) from log-binomial regression model and their 95% confidence intervals.

Results

Baseline characteristics of respondents

Of the 1600 respondents, 1032 were from Bossangoa health district and 568 from Kémo health district. The average age of participants was 31.2 years (± 6.5) (Table 1). Women accounted for 55.5% of respondents (888/1600). Most respondents had lived in their locality for more than 5 years. More than half of the respondents worked in the informal sector (fishing, hunting, agriculture, etc.). At least 60% of participants lived in rural areas and just under half lived along rivers (763/1600).

Table 1. Baseline characteristics of respondents (n = 1600).

Variable Number (%) Mean (sd)
Age (years) 31.22 (6.5)
5–14 123 (07.7)
15–24 200 (12.5)
25–34 424 (26.5)
35–44 354 (22.1)
45 + 499 (31.2)
Sex Male 712 (44.5)
Female 888 (55.5)
Profession
Agriculture / Livestock / Hunting 716 (44.8)
Fishing 168 (10.5)
Public and private sector workers 147 (09.2)
Others * 569 (35.5)
Village or neighbourhood situation
Urban 629 (39.3)
Rural 971 (60.7)
Duration of stay
< 5 years 472 (29.5)
> 5 years 1128 (70.5)
Location of residence
Near rivers 763 (47.7)
Far from rivers 837 (52.3)
Ivermectin uptake in the last campaign
Yes 990 (61.9)
No 610 (38.1)

*: including trading

Prevalence and symptoms of onchocerciasis among respondents

Among the 1600 respondents examined, 357 had onchocerciasis, representing a prevalence of 22.3% (95% CI = 20.27–24.35). At health district level, this prevalence was 26.45% (273/1032) in Bossangoa (95% CI = 23.76–29.14), and 14.79% (84/568) in Kémo (95% CI = 23.53–29.37). The signs and symptoms of onchocerciasis observed among respondents are presented in Table 2.

Table 2. Onchocerciasis status according to signs and symptoms (n = 1600).

Signs and symptoms Total Onchocerciasis status p Prevalence of signs and symptoms (%)
Positive (%) Negative (%)
Nodules on the body
Yes 99 61 (61.6) 38 (38.4) < 0.001 06.19
No 1501 296 (19.7) 1205 (80.3)
Skin changes
Skin desquamation 278 81 (29.1) 197 (70.9) < 0.001 17.35
Leopard skin 101 42 (41.6) 59 (58.4) 06.31
Loss of skin elasticity 33 19 (57.6) 14 (42.4) 02.06
Normal skin 1188 215 (18.1) 973 (81.9)
Eye redness or discomfort
Always 206 85 (41.3) 121 (58.7) < 0.001 12.87
Periodically 309 106 (34.3) 203 (65.7) 19.31
Normal 1085 166 (15.3) 919 (84.7)
Eye examination
Keratitis 279 76 (27.2) 203 (72.8) < 0.001 17.43
Blindness 401 213 (53.1) 188 (46.9) 25.06
Normal 920 68 (07.4) 852 (92.6)
Experience itching
Always 34 13 (38.2) 21 (61.8) 0.010 02.12
Periodically 59 32 (54.2) 27 (45.8) 03.69
Never 1507 312 (20.7) 1195 (79.3)
Experienced seizures
Yes 146 99 (67.8) 47 (32.2) < 0.001 09.12
No 1454 132 (09.1) 1322 (90.9)

Ivermectin uptake and onchocerciasis status

More than one third (38.1%) of the respondents acknowledged that they had not taken ivermectin during the last distribution campaign (610/1600). Of the 367 men taking ivermectin in 2023, 208 (56.7%) were positive for onchocerciasis (compared with 23.9% of women). Among respondents who had taken ivermectin in a single year, 44.6% (291/652) were positive for onchocerciasis, whereas among those who had taken ivermectin for more than two years, 19.5% (66/338) were positive. A significant association was found between not taking ivermectin and positive onchocerciasis status (p < 0.001) (Table 3).

Table 3. Ivermectin uptake and onchocerciasis status (n = 1600).

Variable Ivermectin uptake Onchocerciasis status p
Yes No Yes No
Age group (years)
5–14 88 35 29 59 < 0.001
15–34 429 195 272 157
35 + 473 380 56 417
Sex
Male 367 345 208 159 < 0.001
Female 623 265 149 474
Profession
Agriculture / Livestock / Hunting / Fishing 489 395 225 264 < 0.001
Public and private sector workers 108 39 21 87
Others * 393 176 111 282
Years of ivermectin use
1 652 430 291 361 < 0.001
2+ 338 180 66 272

*: including trading

Factors associated of transmission

In both savannah and forest areas, the common factors incriminated in the transmission of onchocerciasis: young age (PR = 2.44 (1.97–3.03), p < 0.001; 3.63 (2.32–5.70), p < 0.001 respectively), not taking ivermectin (PR = 2.31 (1.86–2.87), p < 0.001; 6.84 (4.42–10.57), p < 0.001 respectively), male sex (PR = 2.54 (2.04–3.16), p <0.001; 1.79 (1.19–2.69), p = 0.002 respectively), living near rivers and in rural areas and the fishing. Fishing was associated with onchocerciasis (PR = 0.33 (0.21–0.50), p < 0.001; PR = 0.29 (0.14–0.61), p = 0.001) (Tables 4 and 5).

Table 4. Factors associated with transmission of Onchocerca volvulus among participants in savannah area in Bossangoa (n = 1032).

Variable Onchocerciasis status Bivariate analysis
Prevalence ratio (95% CI)
p
Positive Negative
Age group (years)
5–14 48 25 2.44 (1.97–3.03) < 0.001
15–34 77 332 0.69 (0.55–0.89) 0.002
35 + 148 402 1
Sex
Male 179 263 2.54 (2.04–3.16) < 0.001
Female 94 496 1
Profession
Agriculture / Livestock / Hunting 52 433 0.39 (0.25–0.60) < 0.001
Fishing 49 68 1.53 (1.02–2.30) 0.017
Public and private sector workers 23 61 1
Others * 149 197 1.57 (1.08–2.27) 0.003
Ivermectin uptake
Yes 96 478 1
No 177 281 2.31 (1.86–2.87) < 0.001
Village or neighbourhoods situation
Urban 98 484 1
Rural 175 275 2.31 (1.86–2.86) < 0.001
Location of residence
Near rivers 169 320 1.80 (1.46–2.23) < 0.001
Far from rivers 104 439 1

Table 5. Factors associated with transmission of Onchocerca volvulus among participants in forest area in Kémo (n = 568).

Variable Onchocerciasis status Bivariate analysis
Prevalence ratio (95% CI)
p
Positive Negative
Age group (years)
5–14 21 29 3.63 (2.32–5.70) < 0.001
15–34 28 187 1.13 (0.71–1.79) 0.307
35 + 35 268 1
Sex
Male 52 218 1.79 (1.19–2.69) 0.002
Female 32 266 1
Profession
Agriculture / Livestock / Hunting 13 218 0.29 (0.14–0.61) 0.001
Fishing 19 32 1.96 (1.05–3.64) 0.016
Public and private sector workers 12 51 1
Others * 40 183 0.94 (0.52–1.68) 0.413
Ivermectin uptake
Yes 24 392 1
No 60 92 6.84 (4.42–10.57) < 0.001
Village or neighbourhoods situation
Urban 18 29 1
Rural 66 455 0.33 (0.21–0.50) < 0.001
Location of residence
Near rivers 53 221 1.83 (1.21–2.76) 0.001
Far from rivers 31 263 1

Discussion

The relevance of the study

Neglected tropical diseases in general, and onchocerciasis in particular, are a real public health concern, not only because of their persistent prevalence, but also because of their gravity, since millions of infected people have a disability-adjusted life years [14]. It is in this context that countries have benefited from the support of numerous partners such as WHO which published NTD Roadmap for 2021–2030 for elimination of transmission (EOT) for onchocerciasis, with 12 countries (including CAR) proposed to be verified for EOT by 2030 [1519].

The CAR has signed up to these declarations and has an obligation to achieve results, as the selected indicators for SDG 3 include those relating to NTDs, particularly target 3.3. Onchocerciasis in CAR has long been considered a curse, especially in the town of Bossangoa, which is reputed to be host to a record number of blind people due to onchocerciasis. The town’s beggars are precisely these blind people, despite receiving aid from charitable associations.

The study showed that the population was young and needs to be protected: average age of was 31.2 years (± 6.5). Over 60.69% (671 /1600) of the population studied live in rural areas and 38.12% (610/1600), which means that strategies need to be developed to reach people in inaccessible areas [6,20,21].

Real burden as neglected tropical disease

Despite several years of efforts to combat onchocerciasis, prevalence remains high in these 2 districts (22.31% [95% CI = 20.27–24.35] in Bossangoa district and 14.79% [95% CI = 23.53–29.37] in Kémo district. The nationwide civil war in the CAR since 2013 has had a detrimental effect on the elimination of onchocerciasis. Some studies have pointed to this aspect [11,22,23]. Participants examined showed the classic signs of skin and eye damage, with an impressive number of blind people (401 in total). A high proportion of respondents, 99/1600 (6.2%) presented with epilepsy. A high proportion of epilepsy was also observed in other onchocerciasis endemic areas with high ongoing O. volvulus such as in the Democratic Republic of Congo, Cameroon and South Sudan [10,2427]. This form of epilepsy is called onchocerciasis-associated epilepsy which includes the nodding syndrome which was recently reported in CAR in an onchocerciasis endemic area where ivermectin was not being distributed [2831].

Transmission factors

The prevalence was significantly higher in men compared to women and was associated with younger age groups. The particularity of the Kémo health district is that this difference is not significant for the 15–34 age group. In this district, secondary school instructors take part in the distribution of ivermectin in schools. In any event, this study showed the vulnerability of children to onchocerciasis [6] and that men are much more exposed to the bites of Simuli than women, because women protect their bodies better than men and most activities near forests and rivers are carried out by men. In Bossangoa district as in Kémo district, many activities occur in the forests and around rivers that expose people to the black flies propagate continued transmission. Proximity to rivers which are breeding sites for the vector have been described to influence the continued O. volvulus transmission by increasing exposure. Men were less likely to take ivermectine. Failure to take ivermectin during distribution campaigns is associated with positive onchocerciasis status. Low ivermectin intake was identified as the main factor explaining the high onchocerciasis endemicity as was observed in many other onchocerciasis endemic areas [29]. So it is importance to increase and sustain high therapeutic coverage and increase distribution frequency if countries are to achieve elimination of O. volvulus transmission.

Strengths and limitations of study

This study shows the high onchocerciasis endemicity and high onchocerciasis associated morbidity in a savannah and a forest area in the CAR. This information should be taken into account in the planning of control activities by the PNLOC. However our study has several limitations. A high prevalence of blindness was observed. However, this may be an overestimation of blindness prevalence in the endemic foci as extra support was provided for the blind in the study area. A strong association between reported seizures and onchocerciasis infection and a very high prevalence of epilepsy was observed. However the diagnosis was not confirmed by a neurologist and the types of seizures, nor the time of onset of the seizures were described. In addition, this study did not describe the reasons why participants did not take ivermectin; this was taken into account in another study.

Conclusions

After more than 20 years of combating onchocerciasis through the community-based distribution of ivermectin, the prevalence of this disease remains worrying in both savannah and forest areas: 26.45% and 14.79% respectively. This prevalence is reduced when the population adheres to taking ivermectin. The burden of onchocerciasis in endemic areas is evident by the high proportion of skin, eye disorders (including blindness) and epilepsy. The main factors in the transmission of the disease in these two areas are young age, male sex, not taking ivermectin and living near rivers. The PNLOC needs to review its planning of activities, ensuring that the population is constantly made aware before drugs are distributed, and increasing the number of days of community-based distribution in order to improve therapeutic coverage.

Acknowledgments

We would like to thank the members of the health management teams in these two health districts, the health centre managers in these districts and the leaders of these two communities who helped to make this study a success.

Data Availability

The datasets used and analysed during the current study are within the manuscript.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Onchocercose [Internet]. [cited 2024 Jun 9]. Available from: https://www.who.int/fr/news-room/fact-sheets/detail/onchocerciasis
  • 2.Onchocerciasis (River Blindness)—Infectious Diseases—MSD Manual Professional Edition [Internet]. [cited 2024 Jun 23]. Available from: https://www.msdmanuals.com/professional/infectious-diseases/nematodes-roundworms/onchocerciasis-river-blindness
  • 3.Kirkwood B, Smith P, Marshall T, Prost A. Relationships between mortality, visual acuity and microfilarial load in the area of the Onchocerciasis Control Programme. Trans R Soc Trop Med Hyg [Internet]. 1983. [cited 2024 Jun 23];77(6):862–8. Available from: https://pubmed.ncbi.nlm.nih.gov/6665841/ doi: 10.1016/0035-9203(83)90308-5 [DOI] [PubMed] [Google Scholar]
  • 4.Guderian RH, Lovato R, Anselmi M, Mancero T, Cooper PJ. Onchocerciasis and reproductive health in Ecuador. Trans R Soc Trop Med Hyg [Internet]. 1997. [cited 2024 Jun 23];91(3):315–7. Available from: https://pubmed.ncbi.nlm.nih.gov/9231206/ doi: 10.1016/s0035-9203(97)90089-4 [DOI] [PubMed] [Google Scholar]
  • 5.World Health Organization. L’onchocercose et la lutte anti-onchocerquienne : rapport. 1995;113. [Google Scholar]
  • 6.Mshana MI, Silvestri V, Mushi V, Bonaventura WM, Tarimo D, Ngasala B, et al. Burden and factors associated with onchocerciasis transmission among school-aged children after more than 20 years of Community Directed Treatment with Ivermectin in Ulanga district, Tanzania: A school-based cross-sectional study. PLOS Glob Public Heal. 2023. May 12;3(5):e0001919. doi: 10.1371/journal.pgph.0001919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Evans TG. Socioeconomic consequences of blinding onchocerciasis in west Africa. Bull World Health Organ [Internet]. 1995. [cited 2024 Jun 23];73(4):495. Available from: /pmc/articles/PMC2486790/?report=abstract [PMC free article] [PubMed] [Google Scholar]
  • 8.Sherwin JC, Lewallen S, Courtright P. Blindness and visual impairment due to uncorrected refractive error in sub-Saharan Africa: Review of recent population-based studies. Br J Ophthalmol. 2012. Jul;96(7):927–30. doi: 10.1136/bjophthalmol-2011-300426 [DOI] [PubMed] [Google Scholar]
  • 9.Ahmed A, Elbashir A, Mohamed AA, Alim AA, Mubarak A, Abdelrahman D, et al. Socioeconomic impacts of elimination of onchocerciasis in Abu-Hamed focus, northern Sudan: Lessons after elimination. BMC Res Notes. 2020. May 26;13(1). • doi: 10.1186/s13104-020-05101-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Colebunders R, Njamnshi AK, Menon S, Newton CR, Hotterbeekx A, Preux PM, et al. Onchocerca volvulus and epilepsy: A comprehensive review using the Bradford Hill criteria for causation. PLoS Negl Trop Dis [Internet]. 2021. Jan 1 [cited 2024 Jun 23];15(1):1–24. Available from: /pmc/articles/PMC7790236/ [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Lakwo T, Oguttu D, Ukety T, Post R, Bakajika D. Onchocerciasis Elimination: Progress and Challenges. Res Rep Trop Med [Internet]. 2020. Oct [cited 2024 Jun 23];11:81. Available from: /pmc/articles/PMC7548320/ doi: 10.2147/RRTM.S224364 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hendy A, Krüger A, Pfarr K, De Witte J, Kibweja A, Mwingira U, et al. The blackfly vectors and transmission of Onchocerca volvulus in Mahenge, south eastern Tanzania. Acta Trop [Internet]. 2018. May 1 [cited 2024 Jun 20];181:50–9. Available from: https://pubmed.ncbi.nlm.nih.gov/29410302/ doi: 10.1016/j.actatropica.2018.01.009 [DOI] [PubMed] [Google Scholar]
  • 13.Kelsey JL. Methods in Observational Epidemiology; Table 12–15 \r. Results from OpenEpi, Version 3, open source Calc [Internet]. 1996. [cited 2024 Jun 20];10:366 pages. Available from: https://search.worldcat.org/title/856808377 [Google Scholar]
  • 14.Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet (London, England) [Internet]. 2020. Oct 17 [cited 2024 Mar 12];396(10258):1204–22. Available from: https://pubmed.ncbi.nlm.nih.gov/33069326/ doi: 10.1016/S0140-6736(20)30925-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ending the neglect to attain the Sustainable Development Goals: A road map for neglected tropical diseases 2021–2030 [Internet]. [cited 2024 Jun 24]. Available from: https://www.who.int/publications/i/item/9789240010352
  • 16.UNSDG | Leave No One Behind [Internet]. [cited 2024 Jun 24]. Available from: https://unsdg.un.org/2030-agenda/universal-values/leave-no-one-behind
  • 17.Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum NK, Hopkins A, et al. Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa. Clin Infect Dis An Off Publ Infect Dis Soc Am [Internet]. 2014. Oct 10 [cited 2024 Mar 12];59(7):923. Available from: /pmc/articles/PMC4166981/ doi: 10.1093/cid/ciu467 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.The Kigali Declaration | Uniting to Combat NTDs [Internet]. [cited 2024 Mar 12]. Available from: https://unitingtocombatntds.org/en/the-kigali-declaration/
  • 19.Elphick-Pooley T, Engels D. World NTD Day 2022 and a new Kigali Declaration to galvanise commitment to end neglected tropical diseases. Infect Dis poverty [Internet]. 2022. Dec 1 [cited 2024 Jun 24];11(1). Available from: https://pubmed.ncbi.nlm.nih.gov/35086566/ doi: 10.1186/s40249-021-00932-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Komlan K, Vossberg PS, Gantin RG, Solim T, Korbmacher F, Banla M, et al. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin. PLoS Negl Trop Dis [Internet]. 2018. Mar 1 [cited 2024 Jun 10];12(3). Available from: https://pubmed.ncbi.nlm.nih.gov/29494606/ doi: 10.1371/journal.pntd.0006312 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Otabil KB, Basáñez MG, Ankrah B, Bart-Plange EJ, Babae TN, Kudzordzi PC, et al. Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study. BMC Infect Dis [Internet]. 2023. Dec 1 [cited 2024 Jun 24];23(1). Available from: /pmc/articles/PMC10655298/ [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Nyagang SM, Cumber SN, Cho JF, Keka EI, Nkfusai CN, Wepngong E, et al. Prevalence of onchocerciasis, attitudes and practices and the treatment coverage after 15 years of mass drug administration with ivermectin in the Tombel Health District, Cameroon. Pan Afr Med J [Internet]. 2020. [cited 2024 Jun 24];35. Available from: /pmc/articles/PMC7321683/ doi: 10.11604/pamj.2020.35.107.16036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Cherif MS, Keita M, Dahal P, Guilavogui T, Habib Beavogui A, Diassy L, et al. Neglected tropical diseases in Republic of Guinea: disease endemicity, case burden and the road towards the 2030 target. Int Health [Internet]. 2023. [cited 2024 Jun 24]; Available from: doi: 10.1093/inthealth/ihad036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Siewe Fodjo JN, Mandro M, Mukendi D, Tepage F, Menon S, Nakato S, et al. Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density. PLoS Negl Trop Dis [Internet]. 2019. Jul 1 [cited 2024 Jun 24];13(7). Available from: https://pubmed.ncbi.nlm.nih.gov/31314757/ doi: 10.1371/journal.pntd.0007300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bhattacharyya S, Melchers NVSV, Fodjo JNS, Vutha A, Coffeng LE, Logora MY, et al. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness. PLoS Negl Trop Dis [Internet]. 2023. May 1 [cited 2024 Jun 24];17(5). Available from: https://pubmed.ncbi.nlm.nih.gov/37235598/ doi: 10.1371/journal.pntd.0011320 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Colebunders R, Hotterbeeks A, Siewe J, Mandro M, Mbonye M, Suykerbuyk P. Epilepsy caused by onchocerciasis is an important public health problem in Africa. Int J Infect Dis 2018; 73: 316–317 doi: 10.1016/j.ijid.2018.04.4134 [DOI] [Google Scholar]
  • 27.Colebunders R, Carter JY, Olore PC, Puok K, Bhattacharyya S, Menon S, Abd-Elfarag G, Ojok M, Ensoy-Musoro C, Lako R, Yibi Logora M. High prevalence of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan: A community-based survey. Seizure 2018; 63: 93–101 doi: 10.1016/j.seizure.2018.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Jada SR, Tionga MS, Siewe Fodjo JN, Carter JY, Logora MY, Colebunders R. Community perception of epilepsy and its treatment in onchocerciasis-endemic villages of Maridi county, western equatoria state, South Sudan. Epilepsy Behav [Internet]. 2022. Feb 1 [cited 2024 Jun 24];127. Available from: https://pubmed.ncbi.nlm.nih.gov/35026562/ doi: 10.1016/j.yebeh.2021.108537 [DOI] [PubMed] [Google Scholar]
  • 29.Forrer A, Wanji S, Obie ED, Nji TM, Hamill L, Ozano K, et al. Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon. BMJ Glob Heal [Internet]. 2021. Jan 1 [cited 2024 Jun 10];6(1):e003248. Available from: https://gh.bmj.com/content/6/1/e003248 doi: 10.1136/bmjgh-2020-003248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Smet E, Metanmo S, Mbelesso P, Kemata B, Fodjo JNS, Boumédiène F, et al. Focus of Ongoing Onchocerciasis Transmission Close to Bangui, Central African Republic. Pathogens. 2020. Apr 30;9(5):337. doi: 10.3390/pathogens9050337 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Metanmo S, Boumédiène F, Preux PM, Colebunders R, Siewe Fodjo JN, de Smet E, Yangatimbi E, Winkler AS, Mbelesso P, Ajzenberg D. First description of Nodding Syndrome in the Central African Republic. PLoS Negl Trop Dis. 2021. Jun 18;15(6):e0009430. doi: 10.1371/journal.pntd.0009430 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012325.r001

Decision Letter 0

Nigel Beebe, Richard Reithinger

30 Aug 2024

Dear Dr Woromogo,

Thank you very much for submitting your manuscript "Factors associated with onchocerciasis transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic: A Cross Sectional Study" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Richard Reithinger

Academic Editor

PLOS Neglected Tropical Diseases

Nigel Beebe

Section Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? YES

-Is the study design appropriate to address the stated objectives? YES

-Is the population clearly described and appropriate for the hypothesis being tested? YES

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? YES

-Were correct statistical analysis used to support conclusions? YES

-Are there concerns about ethical or regulatory requirements being met? NO

Reviewer #2: Are the objectives of the study clearly articulated with a clear testable hypothesis stated? Yes

Is the study design appropriate to address the stated objectives? In the Methods section, there can be some more clarification on what specific skin and eye characteristics researchers looked for (lines 164-165). Additionally, what were the specific disease symptoms in the skin/eyes or skin changes being measured during the community diagnosis process (line 180). What was the definition of epilepsy and seizures given to the respondent (lines 183-184)? Throughout the Data collection and tools section (Methods), The author needs to clarify the difference an individual and community diagnosis. Both types are currently being described as skin and eye symptoms. Also, if the community diagnosis is currently defined as only skin and eye symptoms, why does the author subsequently include epilepsy and seizures?

Is the population clearly described and appropriate for the hypothesis being tested? Yes

Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? Yes

Were correct statistical analysis used to support conclusions? It is unclear how each of the variables were measured separately to limit confounding factors. If they were not truly seperated (other than just considering each variable on their own), it is unsure how a bivariate analysis would show an appropriate correlation.

Are there concerns about ethical or regulatory requirements? No

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: -Does the analysis presented match the analysis plan? more analysis to do

-Are the results clearly and completely presented? Incomplete

-Are the figures (Tables, Images) of sufficient quality for clarity? Tables to improve

Reviewer #2: Does the analysis presented match the analysis plan? Refer to the previously mentioned issues surrounding the chosen statistical analysis methods.

Are the results clearly and completely presented? To improve organization, "some respondents acknowledged that they had not taken ivermectin during the last distribution campaign" (lines 209-210) should be moved to the Ivermectin uptake and onchocerciasis status section and removed from the Baseline characteristics section. This characteristic should also be moved to the appropriate table. Table 1 includes sex and duration of stay, but these factors are not mentioned in the written results of Baseline characteristics of respondents. The statement "living in a rural environment appears to protect against..." is misleading based on what is actually being measured (lines 232-233).

Are the figures (Tables, Images) of sufficient quality for clarity? In Table 1, it is unclear what numbers correspond to participants in the hunting and fishing profession. The term "frequency" is incorrect to describe the number of participants, as this word mostly correlates to an instance of disease or event.

In Table 2, what was the study's definition of nodules and blindness (partial or full blindness)? Additionally, did the symptoms of seizures include epilepsy (as epilepsy was previously mentioned as part of the community diagnosis)? What do the numbers in parenthesis represent (is the unit of measure a percent)?

Need to be consistent throughout all of the tables when including the percentages of participants belonging to each independent variable.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: -Are the conclusions supported by the data presented? yes but incomplete

-Are the limitations of analysis clearly described? see above

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? Yes but does not not enough describe the oncho bvurden of disease

-Is public health relevance addressed? Not enough

Reviewer #2: Are the conclusions supported by the data presented? Given the limitations of the data analysis, it is unclear whether these factors can be considered separate variables contributing to disease transmission.

Are the limitations of analysis clearly described? If proximity to rivers is associated with transmission due to the location of black fly breeding grounds, why did the fishing profession not show any association with transmission? Why is male sex not significant in the Kémo district but significant in the Bossangoa district?

Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? Yes

Is public health relevance addressed? Yes

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Introduction mortality is not only because of blindness but also because of epilepsy

O. volvulus should be in italic

It is mentioned that CAR is among the countries that have made progress in onchocerciasis control and elimination (11,14)

Are these ref showing this? I propose to omit this sentence. Most likely since the start of the civil war in 2013 the programme has been very weak.

How were skin snips read? with an inverted microscope?

Prevalence of symptoms need to be reported in a Table: for example

Nodules 6.2%

Blindness 25%: extremely high How was blindness defined?

Epilepsy 9.1% also extremely high

Line 263: 99/600 (6.19) have onchocerciasis-associated epilepsy (OAE) status. This should be 99/1600

Ref 10 is a good ref for OAE but not appropriate were it is mentioned now.

More ref about epilepsy in oncho areas need to be included certainly the

ref -Desmet E about prevalence of epilepsy in oncho area in the CAR clos to the DRC border and the ref of Methano about nodding syndrome in that area need to be added

Was er a difference in blindness/epilepsy prevalence between forest and Savanna area?

We head nodding seizures reported in persons with epilepsy?

Reviewer #2: The tables should be modified to include consistent units of measurement, i.e. percentages of participants belonging to each variable. Kémo and Bossangoa also were referred to as the forested area and the savannah area, respectively, throughout the study. For consistency, the author should refer to each of these areas by one name (either the health district name or the geographical name) in the methods, results, and conclusion section.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: Interesting paper on onchocerciasis in the CAR

Very little recent information is currently available about the onchocerciasis situation in the CAR. Therefore this paper is very useful.

The extremely high burden of oncho disease because of blindness and OAE needs to be mentioned in the conclusion. This prevalence study was done after an CDTI effort in 2023. Most likely the situation would have been worse before the 2023v distribution.

Weakness of the study is that persons with epilepsy were not examined nor very well interviewed about the type of seizures an time of onset of the first seizures. Are there pigs in the area? Do the persons with epilepsy have access to treatment?

Reviewer #2: There are some weaknesses surrounding the current data analysis. This issue can be improved by an in-depth discussion regarding study's conclusions and limitations or by finding a different way to separate the independent variables.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Colebunders Robert

Reviewer #2: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012325.r003

Decision Letter 1

Nigel Beebe, Richard Reithinger

5 Nov 2024

PNTD-D-24-00890R1Factors associated with Onchocerca volvulus transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic: A Cross Sectional StudyPLOS Neglected Tropical Diseases Dear Dr. Woromogo, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within 30 days Dec 05 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:* A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Richard ReithingerAcademic EditorPLOS Neglected Tropical Diseases Nigel BeebeSection EditorPLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

 Journal Requirements: Additional Editor Comments (if provided):   [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? yes

-Is the study design appropriate to address the stated objectives? yes

-Is the population clearly described and appropriate for the hypothesis being tested? yes

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? yes

-Were correct statistical analysis used to support conclusions? Advice statistician useful

-Are there concerns about ethical or regulatory requirements being met? No

**********

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: -Does the analysis presented match the analysis plan? yes

-Are the results clearly and completely presented? Could be improved

-Are the figures (Tables, Images) of sufficient quality for clarity? Could be improved

**********

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: -Are the conclusions supported by the data presented? Yes but text could be improved

-Are the limitations of analysis clearly described? Yes but text could be improved

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? yes

-Is public health relevance addressed? yes

**********

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Line 72: “the study showed 73 that in both the savannah and the forest, men are particularly at risk, not only because of their 74 activities near rivers, but also because they do not protect their bodies as women do” But men also were less likely to take ivermectin! This seems to be much more important.

Line 95 simuliums should be Simuli (or blackflies) who reproduce

Line 99 the microfilariae do not reproduce

Line 100 A genuine public health problem in terms of morbidity, onchocerciasis is observed in three WHO regions. Sentence is not ok I propose to state “Onchocerciasis is observed in three WHO regions:

Line 131 Are there people rearing pigs?

Line 110 Some of the consequences of this disease on the lives of people in endemic areas 110 remain a cause for concern (3,4,7–10).

Line 117 "treatment increased from 119 million in 2015 to 132 million in 2016” … million persons treated?

Line 119 “The Central African Republic (CAR) has endemic onchocerciasis in 20 health districts in 120 savannah and forest areas.” Should be “In the Central African Republic (CAR) onchocerciasis is endemic in 20 health districts in 120 savannah and forest areas.

Line 161 remove For this study

Line 172 Prevalence of onchocerciasis is determined by individual and community diagnosis. Should be was

Also a skin sample is taken should be was taken

It is not clear when skin snips were taken. On everybody or only when skin or eye manifestations suggested onchocerciasis.

Need to explain this in the methods

Line 180 community diagnosis is epidemiological??? Not clear

Line 181 unclear rewrite

Describe how you assessed symptoms and signs

Line 191: how was onchocerciasis infection status determined ? based on presence or absence of mf in skin snips?

Line 206 omit to this study

Line 208 work should be worked

Line 209 omit Table 1 shows the other characteristics of the participants. Refer to (Table1) after The average age of participants was 31.2 years (± 6.5).

Table 1 improve lay out

You should rounding the number to one decimal place.

Line 213: 357 had onchocerciasis How was this defined symptoms of onchocerciasis?

Table 2 Improve lay out

Title onchocerciasis according to signs and symptoms but Onchocerciasis status based on skin snip results?

Need a separate Table for prevalence of symptoms

Table 4 and 5 transmission of onchocerciasis should be transmission of Onchocerca volvulus

Line 233 omit after several years of community distribution of ivermectin

Line 237 “and the fishing profession” should be “and fishing”

Line 237-9 “In forested areas, profession other than fishing plays no role in onchocerciasis transmission, and living in a rural environment or hunting/agriculture appears to protect against onchocerciasis transmission..” Not clear I propose to state only fishing was associated with onchocerciasis

Line 261 omit studied

Line 262 and 38.12% (610/1600), which means that strategies need to be developed to reach people in remote 263 areas. Unclear, rewrite

Line 271 Similar proportions were.. should be A high prevalence of epilepsy was also

Line 279 -80 explanation is not clear

Line 284-5 rewrite sentence

Line 282-83 men were less likely to take ivermectin. Please mention this. This seems to be a more important factor than the way of covering the body!

Line 297 high prevalence of blindness : no prevalence in the results

298 blin should be blind

Replace very high by high. To calculate the population prevalence you should include in the denominator also the children < 5 years. Do you have this number?

**********

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Robert Colebunders

 [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. If there are other versions of figure files still present in your submission file inventory at resubmission, please replace them with the PACE-processed versions. Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012325.r005

Decision Letter 2

Nigel Beebe, Richard Reithinger

1 Dec 2024

Dear Dr Woromogo,

We are pleased to inform you that your manuscript 'Factors associated with Onchocerca volvulus transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic: A Cross Sectional Study' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Richard Reithinger

Academic Editor

PLOS Neglected Tropical Diseases

Nigel Beebe

Section Editor

PLOS Neglected Tropical Diseases

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-4304-636XX

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

orcid.org/0000-0003-1765-0002

***********************************************************

All of the reviewer's comments have been addressed in full.

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0012325.r006

Acceptance letter

Nigel Beebe, Richard Reithinger

8 Dec 2024

Dear Dr Woromogo,

We are delighted to inform you that your manuscript, "Factors associated with Onchocerca volvulus transmission after 20 years of community treatment with ivermectin in savanah and forest areas in Central African Republic: A Cross Sectional Study," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: RESPONSE TO REVIEWERS.docx

    pntd.0012325.s001.docx (30.3KB, docx)
    Attachment

    Submitted filename: RESPONSE TO REVIEWERS.DOCX

    pntd.0012325.s002.DOCX (27.1KB, DOCX)

    Data Availability Statement

    The datasets used and analysed during the current study are within the manuscript.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES